Trevor Williams/DigitalVision via Getty Images Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares opened 25% lower on January 17th, after the company released a PR suggesting its novel C. diff antibiotic beat out the standard of care, vancomycin, in restoring the gut microbiome during treatment. C. diff antibiotic regimens like vancomycin and Merck’s (MRK) fidaxomicin are known to cause collateral damage to a person’s gut microbiome, leaving them susceptible to often deadly C. diff recurrence. Despite the ...